for Palliative Care, Terminal Illness,
or End-of-Life Distress


This page will allow you to review your initial eligibility and fill out the form below for consideration.

Health Canada has opened the doors for Special Access Program and Section 56 Exemption applications requesting access to Psilocybin-assisted Therapy for Palliative Care and End-of-Life Distress.

At this time, ATMA accepts applications for only those in terminal or palliative conditions.  

You ARE a good candidate for consideration if:

  • you are dealing with a terminal diagnosis or in remission from a life-threatening diagnosis, or receiving palliative care;
  • you are experiencing psychological distress because of your terminal diagnosis and have not responded to other treatment for emotional distress.

  • You are NOT a good candidate for consideration presently if:

    (but please stay connected as we continue to work with Health Canada)

  • you have been diagnosed with Schizophrenia, Borderline Personality Disorder, or Bipolar Disorder;
  • you have experienced traumatic brain injury, experiencing active uncontrolled medical conditions (such as unstable angina, unstable diabetes, uncontrolled asthma/COPD) or experiencing active uncontrolled addictions. We believe that with more study, these conditions may allow for the safe use of psilocybin treatment in the future, but at this time we are not able to process applications with these conditions.
  • Treatments for approved applications will be offered at ATMA Journey Centers. At present, we are located in Calgary, Alberta, and will soon have locations in Ontario and British Columbia.

    Please fill out the following preliminary intake form if you feel you are a good candidate based on the above parameters and we will review this preliminary application and send the next steps for the application process.

    Be the first to know

    Stay informed on our various initiatives and offerings

    Scroll to Top
    We are a proud sponsor of #CatalystSummit2022! Join us at Canada’s premier 3rd annual conference dedicated to psychedelic medicine. Learn more